Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$715,265.00
Award Year:
2004
Program:
SBIR
Phase:
Phase II
Contract:
4R44AR049961-02
Agency Tracking Number:
AR049961
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AGENNIX, INC.
AGENNIX, INC., 8 GREENWAY PLZ, STE 910, HOUSTON, TX, 77046
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOSE ENGELMAYER
(713) 552-1091
JENGELMAYER@AGENNIX.COM
Business Contact:
(713) 552-1091
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing in diabetic ulcers. There are 7.5 million US patients with chronic skin wounds with annual health care costs of $5-9 billion; diabetic ulcers alone cost $4 billion. Current therapies are inadequate with diabetic patients often developing gangrene and needing amputation. Topical rhLF significantly enhanced wound healing in a mouse model, outperforming placebo as well as Regranex, the only biologic approved for chronic wounds. RhLF appears safe and well tolerated in humans, having been administered to 229 patients (topically and orally) without a drug-related serious adverse event. With a good safety profile and promising pre-clinical efficacy, rhLF may prove to be an effective and safe new drug for wound healing. The aims of this study are to evaluate the clinical safety, pharmacokinetics and pharmacodynamics of topical rhLF in patients with diabetic ulcers. Up to 36 patients will be treated for fourteen days with escalating doses of rhLF. Safety will be evaluated clinically and by laboratory results. Incidence of partial and complete wound closure will also be observed. Safety results and any efficacy trends will be used to select rhLF doses for the proposed Phase II trial.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government